Delenex Therapeutics makes two senior appointments
Eric de La Fortelle joins as ceo and Jakob Schlapbach as cfo
La Fortelle was previously global head of external research and technologies at F. Hoffmann-La Roche and more recently global head, emerging technologies. His scientific work contributed to the field of protein structure determination and he was the initial lead author of the SHARP software, which contributed to the resolution of more than 1,000 protein structures by X-ray crystallography.
Schlapbach joined Delenex last December 2010 as cfo. He brings more than 30 years of banking and industrial financing experience to the company. He was cfo of Cytos Biotechnology for more than 10 years until mid-2010 and held the same position at Ascom group between 1994 and 2000.
Thomas Hecht, chairman of Delenex, said: ‘We are pleased and proud to have attracted two managers of such a high calibre to Delenex.’
Delenex Therapeutics AG is developing therapeutic PENTRA antibody fragments targeting serious medical diseases with high unmet need.
Delenex is a spin-off from ESBATech before its acquisition by Alcon in September 2009 and operates out of laboratories and offices in Zürich-Schlieren.
You may also like
Manufacturing
Continuous innovation: redefining the future of pharmaceutical manufacturing
In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced